The well known logistics company, chaired by German billionaire Klaus-Michael Kühne, has been tasked with delivering “medicines and medical goods which are at risk of shortage” into the UK “within days”.

The UK has given the EU a new deadline of two weeks to agree to axe trade checks introduced by the Brexit deal for Northern Ireland, or risk unilateral action by London.

New EU rules come into force today, which could leave British patients exposed after March 29.

The UK’s medicines and devices regulator will stop work that “does not add value” and lose over 100 full time equivalent staff posts as part of its post-Brexit cost cutting drive, a leaked consultation document seen by The BMJ shows. / But experts warned that plans to streamline regulation to speed up the development and approval of new drugs for patients’ benefit carried potential safety risks.

Fears extra expense and paperwork caused by Brexit will make Britain unattractive to global drugmakers.

The UK and EU have reached agreement on how rules in the withdrawal agreement will be implemented, particularly in relation to Northern Ireland.

'What they will actually target is the process by which we control pharmaceutical pricing. That is where they will be pushing - we have to resist them'

The U.K. government urged pharmaceutical companies to stockpile a six-week supply of medicines before the country finally leaves the European Union’s customs regime at the end of the year, in an effort to avoid shortages of drugs.

British pharmacists are struggling to get their hands on certain medicines for cancer, epilepsy, diabetes and menopause as drug supply issues intensify in the country.

Britain must work with other countries to prevent friction on medicine rules post-Brexit to avoid being sidelined by the global drug industry, according to a report from the U.K.’s biggest pharmaceutical lobby group.

Two in three British pharmacies are struggling daily to source painkillers, cancer drugs and other vital medicines, research shows, as the availability of pharmaceuticals becomes increasingly uncertain.

President will put US firms first in UK trade talks, says Kim Darroch

Donald Trump is ready to use trade talks to force the National Health Service to pay more for its drugs as part of his scheme to "put American patients first”.

Inquiry hears of massive extra costs, a mountain of red tape, shrinking investment and chemicals ‘disappearing’ from UK market.

US pharmaceutical firms, known as Big Pharma, want 'full market access for US products' in the NHS which spends £140bn a year.

Sam Bright reports on the disruption, time and cost suffered by one mid-sized company before and after the UK’s formal departure from the European Union

Asked if Washington would be free to ‘jack up prices’, Foreign Secretary Dominic Raab replies ‘The Americans will take their decisions’.

‘No guidance’ has been issued since Chris Grayling’s notorious ferry contracts were axed – despite risk UK will crash out of EU in October. / Medical firms fear the political paralysis created by the Tory leadership race will leave the NHS short of essential drugs after a no-deal Brexit, because no proper planning is taking place.

Officials admit the Conservative leadership contest set back plans to secure enough medicines in the event of a no-deal outcome.

Brexit has been “a horrendous experience for Maltese businesses,” according to the CEO of the Malta Chamber of SMEs.

IN news which will surprise absolutely nobody, the Brexit talks are going terribly and pharmaceutical companies have been told to stockpile six week’s worth of drugs in case of disruption at the end of the transition period.

Sam Bright examines the contribution of Brexit to our current healthcare crisis.

The impact of Brexit has only added fuel to the fire of severe challenges facing health and social care in the UK, warns the Nuffield Trust.

Six years after the referendum we can disentangle the evidence and judge the effects on health and care, says Richard Vize.